An application has been made by Seqirus Australia to the Pharmaceutical Benefits Advisory Committee to list Gardasil 9 on the National Immunisation Program as a 2-dose schedule for females and males aged 12-13 years as part of a school age program for the prevention of the human papilloma virus HPV. This listing if approved will replace the current 3-dose schedule of Gardasil, the 4-valent HPV vaccine. The committee whose role it is to recommend new medicines for listing on the PBS is due to meet again in July 2017.
Gardasil 9 which was approved for use in Australia by the TGA last year is said to be protective against nine HPV types: 6, 11, 16, 18, 31, 33, 45, 52, and 58. On the Gardasil 9 page of Merck’s website, the slogan: Your Child Could Be One Less At Risk For Certain HPV-Related Cancers And Diseases is prominently placed beside several happy, sporty children. Below is the directive to caring parents which reads ‘Help Protect Them With The HPV Vaccine’. However if this vaccine is anything like its predecessor the 4-valent Gardasil, it is likely to be anything but protective. Currently there are tens of thousands of young girls who have become very ill after having their Gardasil shots. Sanevax records the numbers of young people injured and those who have died after HPV vaccinations. These are figures from the United States recording system VAERS and currently the numbers of adverse events are over 50,000 along with 317 deaths. These numbers are mainly from the USA and some parts of Europe and so these totals are far from accurate. Gardasil is authorised for use in 130 countries and 205 million doses have been administered. One would hope that this carnage could not continue and that the HPV vaccinations programs put on hold but instead there is another vaccine in the mix. Far from being protective this new HPV vaccine contains even more aluminium than the current HPV vaccine Gardasil which contains 225 micrograms. One shot of Gardasil 9 has 500 mcg of this neurotoxin. Girls and boys will receive two shots of this new HPV vaccine bringing the total amount of aluminium injected into young bodies up to 1000mcg.
In FDA approved Gardasil 9: Malfeasance or Stupidity?, Norma Erickson has examined the Gardasil 9 package insert where she found that the rate of serious adverse events in the trials of Gardasil 9 was 2.3-2.5%. Doesn’t sound bad but it really is because it means that for every 100,000 people who are given Gardasil 9 there will be 2300 serious adverse events and yet the cervical cancer rate in the US is around 7 women per 100,000. Talk about insanity!
And that’s not all she found when she examined the insert package. During the trials 2.4% of the recipients developed an autoimmune disorder which means that 2400 people could now be suffering from new diseases just because they had this new Gardasil injection. There was also bad news for women who became pregnant during the trials in that 14.1% suffered adverse outcomes. Erickson notes that those who were in the 4-valent Gardasil trials suffered similar and even higher rates of adverse outcomes of 17%. In all 313 women either lost their babies to spontaneous abortion or late fetal death or gave birth to children with congenital anomalies.
Will Gardasil 9 be listed on the PBS after July this year? Or will the PBAC whose job it is to recommend medicines for listing disapprove Seqirus’s request as occurred in November 2006 when CSL applied for the listing of the 4-valent Gardasil? On that occasion the decision not to recommend Gardasil was overturned when Prime Minister John Howard stepped in and promised the public that the vaccine would be approved. In the interests of our children and grandchildren we can hope that Gardasil 9 is not listed on the PBS and if it is we will have to be even more vocal in our opposition to this unnecessary vaccination program that has so far failed to prevent one case of cervical cancer.